ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2329

AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo

Xizhang Sun1, Jie An1, Ting Wang1, Arpit Rathee1, Vernon Alvarez2, Matthew Gonda3, Christian Lood1 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Amytrx Therapeutics Inc., Nashville, TN, 3Amytrx Therapeutics, Nashville, TN

Meeting: ACR Convergence 2023

Keywords: Cutaneous, cytokines, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2326–2351) SLE – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory stimuli induce transcription factors (TFs) such as NF-kB and interferon regulatory factors (IRFs). TFs are transported from cytosol to nucleus to activate genes encoding chemokines and cytokines. Nuclear transport of TFs is performed by importins that comprise a beta chain and different alpha chains that confer substrate specificity for TF nuclear localization sequences (NLS). The alpha-5-containing importin (Impα5) is of particular interest because it transports STAT1, NF-kB, and other stress responsive TFs containing a NLS. AMTX-100 is a 28 amino acid chimeric peptide containing a huFGF4 domain and NF-kB p50 NLS that function to facilitate leukocyte cell penetration and as a nuclear transport checkpoint inhibitor (NTCI), respectively. AMTX-100 is currently in a Phase 2b clinical trial to treat inflammation in eczema. Since Impα5 binds to the NLS of NF-kB p50 as well as STAT1 & 3, we examined the effects of AMTX-100 on inflammatory pathways and Type I interferons (IFN-I), in vitro and in vivo.

Methods: The human monocyte cell line, THP-1 was transfected with 0.1 ug dsDNA in the presence or absence of AMTX-100 and cytokine mRNA expression quantified by qPCR. Neutrophils from healthy volunteers were isolated by density gradient and exposed to either PMA, the ionophore A23187 or immune complexes (IC) containing the lupus antigen SmRNP. NET formation was quantified by release of DNA and MPO as determined by fluorimetry. Female C57BL/6 (B6) mice aged 8-12 weeks were exposed to a single dose of UV (500mJ/cm2) on the dorsal skin. Skin biopsies were obtained before and at 6 and 24 hr post UV exposure. Cytokine gene expression was determined by qPCR. Statistical significance between groups was determined by Student’s t-test.

Results: In vitro studies with THP-1 cells revealed that 1 uM AMTX-100 inhibited IFN-b expression by 82% , and IL-6, TNF and IL-1b by 98%, 84%,and 95% respectively (Fig. 1). In neutrophils incubated with NET-inducing stimuli, AMTX-100 (3 uM) inhibited DNA and MPO release by ~40% in PMA or A23187 stimulated cells but did not affect NET release induced by IC. To determine whether AMTX-100 attenuated the IFN-I response following UV induced inflammation of mouse skin, we applied either 100 or 300 ug AMTX-100 in saline onto the skin before and once daily after UV exposure. As shown in Fig. 2, ISGs, as well IL-1 and IL6 were all reduced in an apparent dose dependent fashion. Similar results were obtained in a second in vivo experiment (not shown).

Conclusion: We conclude that AMTX-100 reduces Type I IFN and NF-kB-dependent inflammatory cytokines from DNA activated human monocytes in vitro. While AMTX-100 had a modest inhibitory effect on NET formation in response to PMA and ionophore stimulation, it did not attenuate NET formation induced by ICs in vitro. When tested in vivo using the lupus-relevant UV skin exposure, we observed a dose-dependent inhibition of several NF-kB-dependent cytokines as well as ISGs. Since AMTX-100 is in clinical trials for inflammatory skin disease, these findings suggest a novel therapeutic approach utilizing importin NTCIs that may be useful for prevention or treatment of cutaneous lupus erythematosus.

Supporting image 1

AMTX_100 inhibits IFN-b and inflammatory cytokine production in vitro. The THP_1 monocyte cell line was incubated with serial 10-fold dilution of AMTX_100 as shown on the X-axis. Left three panels: After 1 hr, cells were transfected with ds-DNA and 6 hrs later the cells were harvested and the RNA expression of IFN-b, IL-6 and TNF quantified by qPCR. The results are shown as expression of the cytokine relative to 18S RNA (R.E. on the Y-axis). Right Panel: The Alamar blue test for viability revealed that the AMTX_100 peptide was non-toxic at the doses used in these experiments.

Supporting image 2

AMTX_100 attenuates the skin IFN and inflammatory response to UV light exposure. C57BL/6 mice were exposed to a single dose of 500 mJ of UV light on the shaved dorsum. As shown on the X-axis, mice received either saline (PBS) or 100 or 300 ug AMTX_100 peptide in PBS before and after UV exposure. Biopsies were obtained at time 0 and at 6 and 24 hr after UV exposure. RNA was extracted and the relative expression of representative ISGs (IP10 and Ifit1) and the inflammatory cytokines (IL-6 and IL_1b) shown on the Y axis. Relative expression of genes prior to UV is shown in orange.


Disclosures: X. Sun: None; J. An: None; T. Wang: None; A. Rathee: None; V. Alvarez: Amytrx Therapeutics, 2; M. Gonda: Amytrx Therapeutics, Inc, 3, 4; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Citryll, 2, Eli Lilly, 5, Gilead, 5, Horizon Therapeutics, 5, Pfizer, 5, Redd Pharma, 5, 11; K. Elkon: None.

To cite this abstract in AMA style:

Sun X, An J, Wang T, Rathee A, Alvarez V, Gonda M, Lood C, Elkon K. AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/amtx-100-a-nuclear-transport-inhibitor-attenuates-inflammatory-cytokine-production-in-vitro-and-following-uv-mediated-skin-inflammation-in-a-mouse-model-of-cutaneous-lupus-erythematosus-in-vivo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/amtx-100-a-nuclear-transport-inhibitor-attenuates-inflammatory-cytokine-production-in-vitro-and-following-uv-mediated-skin-inflammation-in-a-mouse-model-of-cutaneous-lupus-erythematosus-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology